Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Revive Therapeutics (CSE:RVV) has received US FDA approval to move ahead with its evaluation of Bucillamine as a COVID-19 treatment
  • The approval comes after a positive Pre-Investigational New Drug meeting with the regulatory body
  • Revive will now proceed with a Phase 3 confirmatory clinical trial of the drug
  • The FDA has also provided valuable guidance on study design regarding the trial
  • Revive Therapeutics (RVV) is currently up 8.11 per cent to C$0.20 per share, with a market cap of $12.16 million

Revive Therapeutics (CSE:RVV) has received US FDA approval to move ahead with its evaluation of Bucillamine as a COVID-19 treatment.

The blessing from the Food and Drug Administration comes after a successful Pre-Investigational New Drug (pre-IND) meeting. The meeting was announced on April 3 this year.

Revive will now proceed with a Phase 3 confirmatory clinical trial to evaluate the safety and efficacy of Bucillamine.

In further support of the trial, the FDA has also offered guidance regarding study design and outcome measures.

Most importantly, the FDA agreed that Revive could rely on data from a previous IND regarding Bucillamine for gout treatment. As such, the company will not need to undertake any Phase 1 or Phase 2 clinical studies.

Revive, and its Contract Research Organisation (CRO), Pharm-Olam LLC, is now actively incorporating the FDA’s guidance in preparing a Phase 3 package for submission. The company expects to file the final IND within the next 60 days. After this, the Phase 3 trial will commence.

Michael Frank, CEO of Revive Therapeutics, said that the approval to continue studies is a sure sign of Bucillamine’s potential.

“FDA’s support in advising Revive to move directly into a Phase 3 confirmatory trial provides an acknowledgment for the potential of Bucillamine in the treatment of COVID-19.

“Entering into a Phase 3 study is a major milestone for the company. We are excited to unlock the full potential of Bucillamine, not only for this virus, but also for other infectious diseases that we will investigate in the future,” he added.

Revive Therapeutics (RVV) is currently up 8.11 per cent to C$0.20 per share at 12:18pm EST.

More From The Market Herald

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

" Feeding our plant-based future

One of the fastest-growing segments today is the plant-based industry, as the push towards cleaner lifestyles, eating habits, and sustainable living choices fuel

" Salona Global (TSXV:SGMD) expands product distribution

Salona Global (SGMD) has signed an agreement to distribute the Hyperice suite of products and delivered 600 units of its newly launched Mio-Guard.